SIRPA Antibody

What is the mechanism of action for anti-SIRPα antibodies?

Anti-SIRPα antibodies function by blocking the interaction between SIRPα expressed on myeloid cells and CD47 on target cells such as tumor cells. This SIRPα-CD47 interaction normally generates inhibitory "don't-eat-me" signals that prevent phagocytosis. When this interaction is disrupted by anti-SIRPα antibodies, macrophages and other phagocytes can more readily engulf and eliminate tumor cells . Some anti-SIRPα antibodies achieve this blockade through different mechanisms: direct blockers prevent CD47 binding completely, "kick-off" antibodies displace CD47 from antibody-bound SIRPα, and non-blockers bind to SIRPα at sites that don't interfere with CD47 binding . The blocking mechanism enhances innate immune surveillance and can subsequently promote adaptive immunity against tumors through enhanced antigen presentation.

How do researchers determine if an anti-SIRPα antibody binds to all human SIRPα variants?

Determining pan-allelic binding capacity requires comprehensive testing against known SIRPα variants. Researchers typically perform the following procedures:

• Bioinformatic analysis of SIRPA gene sequences from diverse population datasets (e.g., the 1000 Genome Project) to identify major variants

• Verification through Sanger sequencing of exon 3 of the SIRPA gene from diverse individual samples

• Expression of recombinant SIRPα variants as fusion proteins for binding studies

• Affinity measurements using techniques such as:

  • Surface plasmon resonance (SPR) with serial dilutions of SIRPα proteins

  • Octet/bio-layer interferometry with association and dissociation kinetics analysis

  • Cell-based binding assays using cell lines expressing different SIRPα variants

A pan-allelic antibody should demonstrate high-affinity binding to all major SIRPα variants (particularly v1 and v2) with consistent kinetic parameters across variants .

What are the key differences between targeting SIRPα versus CD47 in cancer immunotherapy?

The key differences include:

Targeting SIRPα may avoid safety concerns associated with CD47-targeting agents, particularly the acute anemia and thrombocytopenia frequently observed in clinical trials . Additionally, the restricted expression of SIRPα results in less antigen sink effect, potentially allowing for more efficient target engagement at lower doses .

How can researchers identify and characterize distinct epitope bins for anti-SIRPα antibodies?

Epitope binning is crucial for understanding the diversity of binding modes and functional properties of anti-SIRPα antibodies. Researchers typically employ a multi-step approach:

• Initial screening: Use sandwich-based surface plasmon resonance (SPR) assays where one antibody (ligand) is immobilized on a chip, followed by capture of recombinant SIRPα antigen and interrogation with a second antibody (analyte) .

• Validation: Perform reciprocal binning by reversing the ligand/analyte orientation to confirm competition results .

• Data visualization: Generate sorted heat maps where red boxes indicate competing antibodies (same epitope) and green boxes indicate non-competing antibodies (different epitopes) .

• Complementary techniques:

  • Use structural biology approaches (X-ray crystallography, cryo-EM) to confirm epitope predictions

  • Employ hydrogen-deuterium exchange mass spectrometry to map interaction surfaces

  • Generate antibody:SIRPα:CD47 complexes to understand binding dynamics, particularly for "kick-off" antibodies

• Functional correlation: Correlate epitope bins with blocking activity by assessing the ability of antibodies to disrupt SIRPα-CD47 interactions using SPR with pre-formed SIRPα-CD47 complexes .

Based on published research, anti-SIRPα antibodies typically segregate into approximately six distinct epitope bins: blocking antibodies (bin 1), kick-off antibodies (bin 2), and non-blocking antibodies (bins 3-6) . A comprehensive node plot can be generated to visualize interconnectivities between bins, sequence diversity, and cross-reactive properties .

What strategies can overcome the challenge of SIRPα polymorphism in developing therapeutically effective antibodies?

SIRPα polymorphism presents a significant challenge for developing universally effective antibodies. Researchers have employed several strategies to address this:

• Comprehensive genomic analysis: Analyzing SIRPA sequences from diverse populations to identify major variants. Research indicates that despite extensive polymorphism, only two major SIRPα variants (v1 and v2) are predominant in human populations .

• Targeted immunization approaches: Using immunization strategies that present multiple SIRPα variants to generate antibodies with cross-reactive potential. For example:

  • Immunizing with conserved domains across SIRPα variants

  • Sequential immunization with different variants

  • Co-immunization with multiple variants simultaneously

• Advanced screening technologies: Employing gel-encapsulated microenvironment (GEM) assays with multiple fluorescent reporter beads, each coated with different SIRPα variants, to identify B-cells producing pan-allelic antibodies .

• Engineered binding domains: Designing antibodies that target highly conserved regions of SIRPα that are present across variants .

• Hybridoma technology optimizations: Using specialized hybridoma approaches that enhance the diversity of antibodies generated, increasing the likelihood of identifying rare pan-allelic binders .

This comprehensive approach has led to the successful development of pan-allelic antibodies like ES004-B5, which binds to major human SIRPα variants through a unique epitope with high affinity .

How do researchers evaluate the potential immunogenicity of anti-SIRPα antibodies during preclinical development?

Evaluating immunogenicity of anti-SIRPα antibodies requires a multi-faceted approach:

• Sequence analysis: Examining antibody sequences for potential T-cell epitopes and comparing humanized sequences with germline sequences to identify potential immunogenic regions.

• In silico prediction tools: Using computational algorithms to predict potential immunogenic epitopes within the antibody sequence.

• In vitro assays:

  • Human T-cell proliferation assays to determine if the antibody can induce T-cell activation

  • Allogeneic mixed lymphocyte reactions (MLR) to assess broader immune activation potential

  • Whole blood cytokine release assays to detect potential cytokine storms

• Humanization strategies: For antibodies derived from non-human sources (e.g., chicken), careful humanization processes are employed to minimize immunogenicity while preserving binding properties .

• Non-human primate studies: Conducting repeat-dose toxicity studies in cynomolgus monkeys to evaluate potential immunogenicity in a relevant species .

• Anti-drug antibody (ADA) monitoring: Developing specific assays to detect the development of ADAs in toxicology studies and subsequent clinical trials.

These comprehensive assessments help identify antibodies with lower immunogenicity risk profiles early in development, increasing the likelihood of successful clinical translation.

What are the optimal in vitro assays for evaluating the functional activity of anti-SIRPα antibodies?

Several complementary assays are essential for comprehensively evaluating anti-SIRPα antibody function:

• Binding characterization assays:

  • Surface plasmon resonance (SPR) to determine binding kinetics (kon, koff) and affinity (KD) for different SIRPα variants

  • Cell-based binding using monocyte cell lines (THP-1, U937), primary monocytes, macrophages, and neutrophils to confirm binding to native SIRPα

  • Flow cytometry with fluorescent secondary antibodies to quantify cell surface binding

• Blocking activity assessment:

  • SPR-based competition assays using SIRPα pre-complexed with CD47 to determine if antibodies can block this interaction

  • Classification of antibodies as blockers, non-blockers, or "kick-off" antibodies based on their mechanism of disrupting SIRPα-CD47 interaction

• Functional phagocytosis assays:

  • Co-culture of human macrophages with tumor cell lines (e.g., Burkitt's lymphoma cell lines)

  • Measurement of phagocytosis through fluorescent labeling of target cells and assessment by flow cytometry or microscopy

  • Combination testing with tumor-targeting antibodies (e.g., cetuximab, rituximab) to evaluate synergistic effects

• T-cell activation assessment:

  • OKT3-induced T-cell proliferation assays to evaluate effects on T-cell function

  • Allogeneic mixed lymphocyte reactions to assess broader immune activation

  • Staphylococcus enterotoxin B-induced T-cell proliferation assays

• Safety assessment assays:

  • Hemagglutination assays to evaluate potential interactions with red blood cells

  • Whole blood cytokine release assays to assess inflammatory potential

The combination of these assays provides a comprehensive characterization package that enables selection of optimally functioning antibodies with desirable safety profiles.

What are the critical considerations for designing in vivo studies to evaluate anti-SIRPα antibody efficacy?

Designing robust in vivo studies for anti-SIRPα antibodies requires careful consideration of several key factors:

• Selection of appropriate animal models:

  • Human SIRPα-humanized immunodeficient mice are preferred as standard mouse SIRPα does not interact with human CD47

  • Models should incorporate human tumor cells and human immune cell components

• Study design considerations:

  • Include appropriate control groups (isotype controls, CD47-targeting agents)

  • Evaluate dose-response relationships to determine optimal dosing

  • Consider combination approaches with other immunotherapies or targeted agents

  • Determine appropriate endpoints (tumor growth, survival, immune cell infiltration)

• Pharmacokinetic/pharmacodynamic assessments:

  • Measure antibody exposure in serum and tumor

  • Evaluate target engagement through assessment of receptor occupancy

  • Monitor immune cell activation and phenotypic changes in tumor microenvironment

• Toxicology and safety assessments:

  • Single and repeat-dose toxicity studies in non-human primates (cynomolgus monkeys)

  • Toxicokinetic analysis to understand exposure-toxicity relationships

  • Monitoring of hematological parameters to detect potential effects on blood cells

• Translational biomarker development:

  • Identify and validate biomarkers that correlate with response

  • Develop assays that can be translated to clinical studies

These considerations help ensure that preclinical studies generate robust data to support clinical development while identifying potential issues early in the development process.

How can researchers effectively characterize the binding properties of anti-SIRPα antibodies to different SIRPα alleles?

Comprehensive characterization of binding properties across SIRPα alleles requires a systematic approach:

• Recombinant protein production:

  • Express and purify the major SIRPα variants (v1, v2) as His-tagged or Fc-fusion proteins

  • Ensure proper folding and quality control of recombinant proteins

• Binding kinetics measurement:

  • Use Octet RED96 (ForteBio) or similar bio-layer interferometry systems at controlled temperature (25°C)

  • Capture test antibodies onto anti-human IgG Fc capture biosensors

  • Measure association with serial dilutions of human SIRPα proteins for defined periods (e.g., 40s)

  • Measure dissociation for extended periods (e.g., 100s)

  • Perform curve fitting using 1:1 binding models to determine kon, koff, and KD values

• Cross-reactivity assessment:

  • Test binding to related SIRP family members (SIRPβ, SIRPγ) to determine specificity

  • Evaluate cross-species reactivity (human, cynomolgus, mouse) for translational studies

• Cell-based binding assessments:

  • Test binding to cell lines expressing different SIRPα variants

  • Evaluate binding to primary cells expressing native SIRPα (monocytes, macrophages, neutrophils)

  • Use flow cytometry with appropriate secondary detection antibodies

• Epitope mapping:

  • Perform competition assays between antibodies to identify distinct epitope bins

  • Use structural biology approaches (X-ray crystallography, cryo-EM) for detailed epitope characterization

  • Employ mutagenesis studies to identify critical binding residues

This comprehensive approach enables selection of antibodies with optimal binding characteristics across the range of SIRPα variants present in human populations.

What are the major challenges in developing bispecific antibodies targeting SIRPα and tumor-associated antigens?

Developing effective bispecific antibodies targeting SIRPα faces several significant challenges:

• Format optimization:

  • Determining the optimal bispecific format (e.g., IgG-like, tandem scFv, diabody)

  • Balancing molecular weight, stability, and pharmacokinetic properties

  • Optimizing the spatial arrangement of binding domains to enable simultaneous engagement of both targets

• Affinity balancing:

  • Tuning the relative affinities for SIRPα versus the tumor-associated antigen

  • Ensuring preferential binding to tumor cells while maintaining SIRPα blockade

  • Addressing potential avidity effects that might alter binding characteristics in vivo

• Manufacturing challenges:

  • Addressing potential mispairing of heavy and light chains

  • Optimizing expression systems for high-yield production

  • Ensuring consistency in glycosylation and other post-translational modifications

• Functional assessment:

  • Developing appropriate assays to demonstrate simultaneous binding to both targets

  • Evaluating if the bispecific approach enhances phagocytosis compared to co-administration

  • Assessing potential immunogenicity of novel junctions or linkers

• Preclinical model limitations:

  • Identifying models that appropriately express both human SIRPα and the tumor-associated antigen

  • Developing humanized mouse models that recapitulate human immune system complexity

These challenges require systematic exploration of multiple bispecific formats and careful optimization of binding domains. The potential advantages of bispecific approaches include enhanced tumor targeting, reduced off-target effects, and potentially improved efficacy compared to combination approaches with separate antibodies.

How can researchers address the challenge of resistance to anti-SIRPα antibody therapy?

Addressing resistance mechanisms to anti-SIRPα antibody therapy requires a multi-faceted research approach:

• Characterizing resistance mechanisms:

  • Analyzing changes in SIRPα expression or polymorphism in treatment-resistant samples

  • Evaluating upregulation of alternative "don't-eat-me" signals (e.g., PD-1/PD-L1, MHC class I)

  • Assessing changes in macrophage phenotype and function after treatment

• Developing combination strategies:

  • Combining anti-SIRPα with tumor-targeting antibodies that induce ADCP (antibody-dependent cellular phagocytosis)

  • Exploring combinations with checkpoint inhibitors that target T-cell function (anti-PD-1/PD-L1)

  • Testing combinations with agents targeting alternative macrophage pathways

• Engineering enhanced anti-SIRPα antibodies:

  • Developing antibodies with modified Fc regions to enhance FcγR engagement

  • Creating bispecific antibodies that simultaneously target SIRPα and tumor-associated antigens

  • Engineering antibodies that can modulate additional macrophage functions beyond CD47 blockade

• Identifying predictive biomarkers:

  • Developing assays to predict tumor susceptibility to anti-SIRPα therapy

  • Identifying patient populations most likely to benefit from treatment

  • Monitoring changes in immune cell populations during treatment to predict resistance

• Modulating the tumor microenvironment:

  • Combining with agents that repolarize tumor-associated macrophages from M2 to M1 phenotype

  • Testing approaches that enhance recruitment of fresh myeloid cells to the tumor site

These strategies aim to overcome potential resistance mechanisms and enhance the durability of responses to anti-SIRPα therapy.

What novel approaches are being explored to enhance macrophage-mediated phagocytosis beyond SIRPα blockade?

Researchers are exploring several innovative approaches to enhance macrophage-mediated phagocytosis beyond simple SIRPα blockade:

• Targeting multiple phagocytic checkpoints:

  • Combining SIRPα blockade with inhibition of other "don't-eat-me" signals

  • Developing agents that simultaneously block SIRPα and enhance "eat-me" signals like calreticulin exposure

• Macrophage reprogramming strategies:

  • Using agents that shift tumor-associated macrophages from immunosuppressive M2 to proinflammatory M1 phenotype

  • Developing approaches to enhance macrophage recruitment and activation in the tumor microenvironment

• Advanced antibody engineering:

  • Creating trispecific antibodies that simultaneously block SIRPα, engage tumor antigens, and activate macrophage Fcγ receptors

  • Developing antibody-drug conjugates that deliver immunomodulatory payloads to macrophages following SIRPα engagement

• Combination with innate immune stimulators:

  • Testing SIRPα blockade with toll-like receptor (TLR) agonists to enhance macrophage activation

  • Combining with CD40 agonists to promote macrophage activation and antigen presentation

• Cell therapy approaches:

  • Engineering macrophages with modified SIRPα signaling domains

  • Developing CAR-macrophages (CAR-Ms) that combine enhanced tumor recognition with disabled inhibitory signaling

• Microenvironment modulation:

  • Combining SIRPα blockade with agents that reduce tumor-derived suppressive factors

  • Developing approaches to enhance tumor antigen presentation following phagocytosis

These approaches reflect the understanding that effective macrophage-mediated tumor elimination likely requires multi-faceted interventions beyond simply blocking the SIRPα-CD47 interaction.

What are the critical quality attributes for anti-SIRPα antibodies in preclinical development?

Developing successful anti-SIRPα antibodies requires careful consideration of several critical quality attributes:

• Binding characteristics:

  • High affinity binding to all major SIRPα variants (pan-allelic binding)

  • Appropriate binding kinetics with optimized association and dissociation rates

  • Specific binding without cross-reactivity to related family members (unless desired)

  • Stability of binding under physiological conditions

• Functional properties:

  • Potent blockade of SIRPα-CD47 interaction measured by appropriate blocking assays

  • Strong enhancement of macrophage phagocytosis in relevant in vitro models

  • Efficacy in combination with tumor-targeting antibodies

  • Minimal effects on normal cells expressing CD47

• Biophysical attributes:

  • Thermal stability (Tm and Tagg) within acceptable ranges

  • Minimal aggregation during manufacturing and storage

  • Appropriate charge variants profile

  • Consistent glycosylation pattern

• Safety parameters:

  • Low immunogenicity risk profile

  • Absence of cytokine release in whole blood assays

  • No hemagglutination of red blood cells

  • Acceptable toxicology profile in relevant species (cynomolgus monkeys)

• Manufacturability considerations:

  • High expression levels in production cell lines

  • Consistent product quality attributes

  • Stability under typical storage conditions

These attributes should be systematically assessed during antibody development and optimization to select candidates with the highest probability of successful clinical translation.

How can researchers optimize assays to evaluate anti-SIRPα antibody-mediated phagocytosis?

Optimizing phagocytosis assays for anti-SIRPα antibody evaluation requires careful attention to multiple parameters:

• Macrophage preparation and conditioning:

  • Use consistent protocols for generating human macrophages from monocytes

  • Consider testing different polarization states (M0, M1, M2) to understand effects in different macrophage phenotypes

  • Evaluate fresh vs. cryopreserved macrophages for assay reproducibility

• Target cell selection and preparation:

  • Choose appropriate tumor cell lines based on research questions (e.g., hematological vs. solid tumors)

  • Standardize target cell labeling methods (fluorescent dyes, pH-sensitive dyes, or reporter systems)

  • Consider expression levels of "eat-me" signals (e.g., calreticulin) and "don't-eat-me" signals (CD47)

• Assay format optimization:

  • Determine optimal effector:target ratios through systematic titration

  • Establish appropriate incubation times to capture phagocytosis kinetics

  • Develop consistent washing protocols to remove non-phagocytosed cells

• Readout methodology selection:

  • Flow cytometry for high-throughput quantitative assessment

  • Microscopy (fluorescence, confocal) for detailed visualization and confirmation

  • Real-time imaging for kinetic analysis

  • Consider dual-labeling approaches to distinguish binding from internalization

• Controls and standardization:

  • Include appropriate positive controls (e.g., anti-CD47 antibodies, SIRPαFc proteins)

  • Use isotype controls to account for Fc-mediated effects

  • Develop standard operating procedures to ensure consistency between experiments

  • Consider including reference standards for inter-laboratory comparison

• Combination testing approaches:

  • Establish protocols for testing anti-SIRPα antibodies in combination with tumor-targeting antibodies

  • Develop isobologram analyses to determine synergistic, additive, or antagonistic effects

  • Consider three-dimensional interaction models for complex combinations

These optimizations ensure that phagocytosis assays provide reliable, reproducible data that accurately reflects the functional activity of anti-SIRPα antibodies in promoting tumor cell clearance.

What biomarkers should researchers consider for patient selection in anti-SIRPα antibody clinical trials?

Identifying appropriate biomarkers for patient selection is critical for successful clinical development of anti-SIRPα antibodies:

• Target-related biomarkers:

  • SIRPα expression levels on peripheral blood and tumor-infiltrating myeloid cells

  • SIRPα genotype/variant analysis to ensure coverage by pan-allelic antibodies

  • CD47 expression levels on tumor cells

  • Ratio of CD47 to "eat-me" signals like calreticulin on tumor cells

• Tumor microenvironment characteristics:

  • Quantification and phenotyping of tumor-associated macrophages (TAMs)

  • M1/M2 polarization status of TAMs

  • Myeloid-to-lymphoid cell ratios within tumors

  • Expression of alternative immune checkpoints

• Functional immune assessments:

  • Ex vivo phagocytosis assays using patient-derived samples

  • Assessment of baseline phagocytic capacity of patient macrophages

  • Evaluation of antibody-dependent cellular phagocytosis potential

• Genomic/transcriptomic biomarkers:

  • Gene expression signatures associated with myeloid cell function

  • Tumor mutational burden and neoantigen load

  • Expression of genes involved in phagocytosis pathways

• Combination therapy considerations:

  • For combinations with tumor-targeting antibodies: expression of target antigens

  • For combinations with checkpoint inhibitors: PD-L1 expression, T-cell infiltration

  • For combinations with chemotherapy: markers of immunogenic cell death

These biomarkers should be systematically evaluated in early-phase clinical trials to identify patient populations most likely to benefit from anti-SIRPα therapy and to develop companion diagnostic approaches for later-stage development.

How should researchers design combination strategies with anti-SIRPα antibodies to maximize clinical efficacy?

Designing effective combination strategies with anti-SIRPα antibodies requires a systematic approach:

• Mechanistic rationale-based combinations:

  • Tumor-targeting antibodies (e.g., rituximab, cetuximab) to provide "eat-me" signals through Fc-FcγR interactions

  • Checkpoint inhibitors (anti-PD-1/PD-L1) to enhance T-cell responses following increased antigen presentation

  • Chemotherapies that induce immunogenic cell death to enhance "eat-me" signals

  • Macrophage-polarizing agents to shift TAMs toward pro-inflammatory phenotypes

• Sequence and scheduling optimization:

  • Determine optimal timing (concurrent vs. sequential administration)

  • Establish dose ratios that maximize synergy while minimizing toxicity

  • Consider intermittent dosing schedules to reduce potential immune suppression

• Patient selection strategies:

  • Identify biomarkers predictive of response to specific combinations

  • Develop algorithms integrating multiple biomarkers for patient stratification

  • Consider tumor type-specific combination approaches

• Monitoring pharmacodynamic effects:

  • Measure changes in immune cell populations following treatment

  • Assess alterations in cytokine/chemokine profiles

  • Evaluate tumor biopsies for evidence of enhanced phagocytosis and subsequent adaptive immune activation

• Novel combination concepts:

  • Bispecific or multispecific antibodies combining SIRPα blockade with other modalities

  • Combination with emerging innate immune modulators (e.g., STING agonists, TLR ligands)

  • Integration with adoptive cell therapy approaches

Current evidence suggests that anti-SIRPα antibodies like ES004-B5 show superior antitumor activity when combined with tumor-targeting antibodies both in vitro and in vivo . These combinations enhance the initial phagocytosis signal while removing the inhibitory "don't-eat-me" signal, creating conditions for maximal macrophage activation and tumor cell clearance.

What emerging technologies could advance anti-SIRPα antibody development and characterization?

Several cutting-edge technologies are poised to accelerate anti-SIRPα antibody research:

• Advanced antibody discovery platforms:

  • Single B-cell isolation and sequencing technologies for rapid identification of diverse anti-SIRPα antibodies

  • Machine learning approaches to predict optimal antibody sequences for pan-allelic binding

  • Gel-encapsulated microenvironment (GEM) assays for high-throughput screening of antibody-secreting B cells

• Structural biology innovations:

  • Cryo-electron microscopy for visualization of SIRPα-antibody complexes

  • Hydrogen-deuterium exchange mass spectrometry for epitope mapping

  • Computational modeling to predict antibody-antigen interactions across SIRPα variants

• Advanced imaging techniques:

  • Intravital microscopy to visualize phagocytosis in real-time in vivo

  • Multiplexed imaging mass cytometry for comprehensive analysis of tumor microenvironment

  • Super-resolution microscopy to study receptor clustering and signaling dynamics

• Single-cell analysis technologies:

  • Single-cell RNA sequencing to characterize macrophage populations before and after treatment

  • Cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) to correlate protein expression with transcriptional profiles

  • Single-cell spatial transcriptomics to map macrophage-tumor cell interactions

• Genome editing approaches:

  • CRISPR-Cas9 screens to identify additional regulators of the SIRPα-CD47 axis

  • Generation of improved humanized mouse models expressing human SIRPα variants

  • Engineering of macrophages with enhanced phagocytic capacity

These technologies will enable more precise characterization of anti-SIRPα antibodies and potentially reveal new therapeutic strategies targeting the SIRPα-CD47 axis and related pathways.

How might anti-SIRPα antibodies be utilized beyond cancer immunotherapy?

While cancer immunotherapy is the primary focus for anti-SIRPα antibodies, their potential extends to several other therapeutic areas:

• Infectious disease applications:

  • Enhancing phagocytosis of antibiotic-resistant bacteria

  • Promoting clearance of intracellular pathogens that evade immune detection

  • Combining with antibiotics for synergistic antimicrobial effects

• Autoimmune disease modulation:

  • Targeting specific SIRPα+ myeloid populations involved in autoimmune pathogenesis

  • Developing antibodies that selectively modulate rather than block SIRPα signaling

  • Creating bispecific approaches that specifically target pathogenic immune complexes

• Neurological applications:

  • Enhancing microglial phagocytosis of protein aggregates in neurodegenerative diseases

  • Promoting clearance of amyloid-β or tau in Alzheimer's disease

  • Targeting neuroinflammatory processes in multiple sclerosis

• Fibrotic disease treatment:

  • Modulating macrophage functions in fibrotic tissues

  • Promoting clearance of pro-fibrotic factors

  • Reprogramming tissue-resident macrophages to promote resolution of fibrosis

• Transplant medicine:

  • Modulating myeloid cell responses to allografts

  • Combining with conventional immunosuppressants for synergistic effects

  • Developing approaches that specifically target donor-reactive immune responses

These applications would require careful optimization of anti-SIRPα antibodies for the specific disease context, potentially including different epitope targeting, modified pharmacokinetic properties, or novel delivery approaches depending on the therapeutic goal.

What are the implications of SIRPα polymorphism for global development of anti-SIRPα therapeutics?

SIRPα polymorphism has important implications for the global development of anti-SIRPα therapeutics:

• Population-specific considerations:

  • Distribution of SIRPα variants differs across ethnic groups and geographic regions

  • Comprehensive analysis of SIRPA sequences from diverse populations (e.g., the 1000 Genome Project) is critical for understanding global variant distribution

  • Clinical trial design should ensure inclusion of populations with different SIRPα variants

• Pan-allelic antibody development challenges:

  • Developing antibodies that recognize all major SIRPα variants is essential for global applicability

  • Targeting conserved epitopes across SIRPα variants is a key strategy for pan-allelic binding

  • Extensive characterization across variants is required to ensure consistent functional activity

• Regulatory considerations:

  • Regulatory agencies may require demonstration of efficacy across SIRPα variants

  • Companion diagnostics for SIRPα variant determination might be necessary in some regions

  • Special population analyses may be needed in clinical trials

• Manufacturing and quality control implications:

  • Assays must be developed to confirm consistent binding to all relevant SIRPα variants

  • Reference standards representing major variants should be included in quality control testing

  • Stability studies should evaluate potential differential effects on binding to different variants

• Clinical trial design considerations:

  • Stratification by SIRPα variant may be necessary in early clinical development

  • Biomarker studies should evaluate impact of SIRPα polymorphism on treatment response

  • Post-marketing surveillance should monitor for variant-specific efficacy differences

Understanding and addressing these implications is essential for developing anti-SIRPα therapeutics with global applicability. Current research indicates that despite extensive polymorphism in the SIRPA gene, targeting specifically designed conserved epitopes can overcome these challenges, as demonstrated by pan-allelic antibodies like ES004-B5 .